



<http://researchspace.auckland.ac.nz>

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the [Library Thesis Consent Form](#) and [Deposit Licence](#).

Note : Masters Theses

The digital copy of a masters thesis is as submitted for examination and contains no corrections. The print copy, usually available in the University Library, may contain corrections made by hand, which have been requested by the supervisor.

The Development of PI3K Inhibitors as Anticancer Drugs

Andrew James Marshall

A thesis submitted in fulfilment of the requirements for the degree of Doctor
of Philosophy in Chemistry

Auckland Cancer Society Research Centre
The University of Auckland

July 2010

Abstract

Phosphatidylinositol 3-kinases (PI3Ks) are a lipid enzyme family that are vitally important regulators of intracellular signalling pathways which control cellular activities including cell survival, growth and proliferation. Deregulation of the PI3K signalling cascade has been observed in a broad range of human diseases including cancer, diabetes, thrombosis, immunity and inflammatory disorders. With the discovery of PI3K's link to a variety of diseases, there has been a race to produce ATP competitive inhibitors as therapeutic agents against the Class I PI3K isozymes. Herein, compounds from two structurally distinct chemotypes were synthesised and their activity and specificity characterized against isolated Class PI3K enzymes and two cellular lines.

The aryl morpholine containing pyrido[1,2-*a*]pyrimidines probed the requirements of the Class IA PI3K active sites through modification of the pendant C9 position. Interestingly, no compound synthesised exhibited superior activity towards the p110 β enzyme than TGX-221 (**1.14**). The second series of compounds probed the requirements of the thiazole-linked pyrazolo[1,5-*a*]pyridine **4.41B**, identified through scaffold hopping studies using the novel p110 α selective inhibitor PIK-75 (**1.34**). Although **4.41B** was not synthetically accessible, analogues explored alternative linkers and substitution of the 2-methyl-5-nitrobenzene ring, to investigate the effect on p110 α selectivity and potency. The sulfone-pyrazole linker group in (**5.5**) was found to be critical, with alternative linker groups in the thiazole series SO₂CH₂ **4.123**, CH₂ **4.122**, CHOH **4.114** and linker absent **4.108** ablating activity, while activity was retained by thiazole-CH₂SO₂ **4.124**.

As the complexes between the pyrido[1,2-*a*]pyrimidine and pyrazolo[1,5-*a*]pyridine chemotypes with the active sites of p110 β and p110 α respectively are not known, docking simulations were performed using structural p110 β models and p110 α (pdb:2RD0) respectively to understand the molecular basis for the isoform selectivity exhibited by the two chemotypes. Suitable docking methods were obtained by first investigating the ability of three docking protocols GOLD, SURFLEX and AutoDock to find and correctly rank an experimentally derived conformation both retrospectively (rescoring), where the compounds were docked back into the p110 γ crystal, and prospectively, where the ligands were docked into the apo p110 α (2RD0).

Acknowledgments

I was very fortunate to work alongside my supervisor Associate Professor Gordon Rewcastle an active bench chemist and group leader. His boyish enthusiasm for chemistry, amazing memory and hard work, to make a difference for cancer patients was a real inspiration for me. Most of all Gordon has been a great friend, confident and chauffeur to my mother and me for many years.

It was a pleasure to work with Dr Jackie Kendall who always kind, ready to listen and encouraging and greatly supported my work on the thiazole linked-pyrazolo[1,5-*a*]pyridines.

I am indebted to Dr Jack Flanagan who shared and taught me how to use a bewildering array of computation tools, and who also spent countless hours of his time, helping me structure and correct the modelling and biological sides of the project into a cohesive whole.

Thanks to my main supervisor Professor Bill Denny who took me on, provided office and lab space in an incredible working environment with world class researchers, and a challenging project that became a component of a drug development program. I am also appreciative to Bill for securing a generous scholarship from the Maurice Wilkins Centre for Molecule Biodiscovery which made the generation of this work possible. I sincerely hope that I am not the last chemistry student for the next 20 years to work in the unique multidisciplinary organization of the ACSRC.

I am appreciative towards my fellow chemists on the PI3K project Swarna Gamage, Anna Giddens and Sophia Tsang for their helpful advice, and who did an amazing amount of work to meet commercial deadlines imposed by Pathway Therapeutics.

I am grateful to our amazing NMR technologists Dr Maruta Boyd, Dr Shannon Black and Dr Stephanie Maurer for their work on obtaining spectra, and assistance in interpreting spectra. I would also like to thank Dr Brian Palmer and Adrian Blaser for looking after the LCMS and element analysis services.

I am appreciative to Mr Wilson Sun for distilling solvent for column chromatography, finding and purchasing chemicals and the best possible price and maintaining a laboratory store second to none. Further, my thanks to Mr Sisira Kumara and Mrs Karin Tan for their analytic and preparative HPLC work on my compounds respectively.

Thanks to Professor Bruce Baguley who headed work on cancer biology aspect of the PI3K project, and whom provided many mornings of stimulated discussion whilst walking through Newmarket and the Auckland Domain. I would also like to thank Claire Mawson, Jo Yu for testing my insoluble compounds in laborious isolated enzyme assays, Steve Jamieson Emma Richardson, Wayne Joseph, Laura Broome and my mother Elaine, for cell culture work and Phil Kestell and Ripu Singh who conducted the pharmacology aspect of the project.

Thanks to our collaborators from the Department of Molecular Medicine and Pathology headed by Professor Peter Shepherd and the team consisting of Christina Buchanan, Claire Chaussade, Kitty Cho, Sharada Kolekar, Woo-Jeong Lee and Alisha Malik who conducting isolated enzyme assays.

I am grateful to my friends and colleges of the “Coffee Crew” Drs Amir Ashoorzadeh, Anna Giddens, Hamish Sutherland, Daniel Heinrich, Kit Tsang, Dani Lyons, Patrick O’Connor, Mrs Leigh-Anne Parish and Miss Charu Reddy, for the laughs and good times.

I would like to thank my close friends; Veeb and Karmon, Scott and Joe, Beau and Merita and Paul and Kim for their love, support and fun times over the long years.

A special thanks to my girlfriend Jessica Dunn who has loved, supported me, and put up with my moods over the years, and to her family (especially her father who took a keen interest in my studies).

Finally, a big thank you goes to my family, especially my mother, father, and brother Geoffrey for their love, support and encouragement over the years.

Table of Contents

Abstract	ii
Acknowledgments	iii
Declaration and Preface	xi
Abbreviations Chemistry.....	xii
Amino acids.....	xiv
Abbreviations (Molecular and Cellular biology)	xiv
Chapter 1. Introduction	1
1.1 Cancer	1
1.2 Phosphatidylinositol 3-kinases (PI3Ks).....	2
1.2.1 Class IA PI3K.....	3
1.2.2 Class IB PI3K	4
1.2.3 Class II PI3K	6
1.2.4 Class III PI3K	6
1.2.5 Classification of PI3K family	6
1.3 Phosphatidylinositol 3-kinases (PI3Ks) Signalling Pathways	7
1.3.1 PI3K pathway and the implications for cancer.....	8
1.4 PI3K inhibition.....	12
1.4.1 p110 γ /ATP (1.3).....	12
1.4.2 Wortmannin (1.4)	13
1.4.3 Staurosporine (1.8)	15
1.4.4 Low affinity natural products	15
1.4.5 LY294002 (1.12)	16
1.4.6 TGX-221 (1.14).....	17
1.4.7 PIK-39 (1.15).....	18
1.4.8 PIK-90 (1.17).....	19
1.4.9 AS-605240 (1.18) and AS-604850 (1.19)	19
1.4.10 Imidazo[1,2- <i>a</i>]pyridines (PIK 75)	20

1.4.11	PI-103	23
1.4.12	The PI-103 analogue GDC-0941	23
1.4.13	ZSTK474	24
1.4.14	NVP-BEZ235	24
1.5	Conclusion	25
1.6	Objectives	26
Chapter 2.	Pyrido[1,2- <i>a</i>]pyrimidines	28
2.1	Introduction.....	28
2.2	29
2.3	Development of the aryl morpholine pharmacophore	29
2.4	Pyrido[1,2- <i>a</i>]pyrimidines as a potential anticancer agents	30
2.1	Aims.....	31
2.1.1	Proposed synthetic route to key intermediate TGX-066	33
2.2	Aniline and benzylamine derivatives.....	34
2.3	Amide derivatives	37
2.4	Carbamate, sulfonamide and urea derivatives	41
2.5	Carboxamide derivatives	41
2.6	Benzylamine Substituents.....	44
2.7	Benzylic analogues	50
2.8	Summary.....	52
Chapter 3.	Structural analysis of the active site of PI3K and the molecule features and interactions with small molecule inhibitors	55
3.1	Aim	58
3.2	Comparative Modelling: Material and Methods.....	58
3.2.1	Target and template alignment.....	58
3.2.2	Model construction.....	58
3.2.3	Docking and predictive docking in p110 γ and p110 α active sites	59
3.2.4	GOLD 4.0.....	59
3.2.5	AutoDock 4.0.	59

3.2.6	SURFLEX 2.30	60
3.2.7	Preparation of retrospective Table 3.3 and predictive Table 3.4 docking tables.....	60
3.2.8	Molecular docking of pyrido[1,2- <i>a</i>]pyrimidines analogues	60
3.3	Results and Discussion	60
3.3.1	Class I PI3K kinase domain sequence comparison	60
3.4	Comparative p110 β kinase domain Modelling results.....	63
3.4.1	p110 α (pdb:2RD0) template	63
3.4.2	p110 γ (pdb:1E7V) template.....	63
3.4.3	p110 γ (pdb:2CHW) template.....	64
3.4.4	Combined use of p110 α and p110 γ structural templates.....	64
3.4.5	Structure of the p110 β active site	65
3.5	Comparing the PI3K active site using different docking programs.....	66
3.5.1	Redocking of known p110 γ -inhibitor complexes.....	66
3.5.2	Predictive docking in the p110 α structure (pdb:2RD0)	71
3.6	Investigation of the benzylic series.....	77
3.6.1	Investigation of heteroatom dependency in the pedant C9 group	78
3.6.2	Investigation of the aniline series	79
3.6.3	Investigation of the benzylamine series.....	80
3.6.4	Investigation of the carboxamide series	82
3.6.5	Investigation of the amide series	83
3.7	Investigation of p110 β selectivity for pyrido[1,2- <i>a</i>]pyridines by molecular docking	84
3.7.1	Probing the specificity pocket	88
3.7.2	Aniline analogues	89
3.7.3	Benzylamine analogues	90
3.7.4	Amide and Carboxamides	91
3.8	Summary	92
Chapter 4.	Pyrazolo[1,5- <i>a</i>]pyridines	94
4.1	Introduction.....	94
4.1.1	Structural activity relationships of sulfonyl hydrazones	94

4.1.2	Investigation of the key imidazo[1,2- <i>a</i>]pyridine chromophore.....	94
4.1.3	Investigation of the pyrazolo[1,5- <i>a</i>]pyridine C-5 position.....	96
4.1.4	Investigation of binding modes of PIK-75 analogues	97
4.2	Planned investigation of pyrazolo[1,5- <i>a</i>]pyridines containing a thiazole linker	98
4.2.1	Synthesis of key pyrazolo[1,5- <i>a</i>]pyridine intermediate 4.45	101
4.2.2	Synthesis of <i>tert</i> -butyl 3-acetylpyrazolo[1,5- <i>a</i>]pyridin-5-ylcarbamate (4.56).	102
4.3	Synthetic methods to 4-(5-bromopyrazolo[1,5- <i>a</i>]pyridin-3-yl)-1,3-thiazol-2-yl 2-methyl-5-nitrophenyl sulfide (4.42)	107
4.4	Synthesis of 4-(5-bromopyrazolo[1,5- <i>a</i>]pyridin-3-yl)-1,3-thiazol-2-yl 3-nitrophenyl sulfide (4.72)	108
4.4.1	Oxidation of 4-(5-bromopyrazolo[1,5- <i>a</i>]pyridin-3-yl)-1,3-thiazol-2-yl 3-nitrophenyl sulfide (4.72)	110
4.5	Attempted synthesis of 4-(5-bromopyrazolo[1,5- <i>a</i>]pyridin-3-yl)-1,3-thiazol-2-yl 2-methyl-5-nitrophenyl sulfone (4.76)	111
4.6	Synthesis of 5-bromo-3-{2-[(2-methylphenyl)sulfinyl]-1,3-thiazol-4-yl}pyrazolo[1,5- <i>a</i>]pyridine (4.91)	116
4.7	Synthesis of 5-bromo-3-{2-[(5-fluoro-2-methylphenyl)sulfinyl]-1,3-thiazol-4-yl}pyrazolo[1,5- <i>a</i>]pyridine (4.93)	117
4.8	Synthesis of <i>N</i> -[4-(5-bromopyrazolo[1,5- <i>a</i>]pyridin-3-yl)-1,3-thiazol-2-yl]-2-methyl-5-nitrobenzenesulfonamide (4.95)	118
4.8.1	Methylation of <i>N</i> -[4-(5-bromopyrazolo[1,5- <i>a</i>]pyridin-3-yl)-1,3-thiazol-2-yl]-2-methyl-5-nitrobenzenesulfonamide (4.95)	120
4.9	Synthesis of 4-(5-bromopyrazolo[1,5- <i>a</i>]pyridin-3-yl)- <i>N</i> -(2-methyl-5-nitrophenyl)-1,3-thiazol-2-amine (4.101)	122
4.10	Synthesis of 5-bromo-3-[2-(2-methyl-5-nitrophenyl)-1,3-thiazol-4-yl]pyrazolo[1,5- <i>a</i>]pyridine (4.108)	123
4.11	Planned synthesis of [4-(5-bromopyrazolo[1,5- <i>a</i>]pyridin-3-yl)-1,3-thiazol-2-yl](2-methyl-5-nitrophenyl)methanone (4.112)	123
4.11.1	Identification of [4-(5-bromopyrazolo[1,5- <i>a</i>]pyridin-3-yl)-1,3-thiazol-2-yl](2-methyl-5-nitrophenyl)methanol (4.114)	124

4.12	Synthesis of 5-bromo-3-[2-(2-methyl-5-nitrobenzyl)-1,3-thiazol-4-yl]pyrazolo[1,5- <i>a</i>]pyridine (4.122).....	124
4.12.1	Synthesis of 5-bromo-3-{2-[(2-methyl-5-nitrobenzyl)sulfonyl]-1,3-thiazol-4-yl-2-pyrazolo[1,5- <i>a</i>]pyridine (4.124)	126
4.12.2	Synthesis of 5-bromo-3-(2-{[(2-methyl-5-nitrophenyl)sulfonyl]methyl}-1,3-thiazol-4-yl)pyrazolo[1,5- <i>a</i>]pyridine (4.123)	126
4.13	Investigation into substitution of the 4-position of the benzene ring	127
4.14	Summary	129
Chapter 5.	Molecular modelling of the Pyrazolo[1,5- <i>a</i>]pyridines	130
5.1	Introduction.....	130
5.1	Aims.....	130
5.2	Molecular docking methods.....	131
5.3	Biological results for the pyrazolo[1,5- <i>a</i>]pyridines analogues	131
5.3.1	The effect of the linker region on isolated enzyme activity	131
5.3.2	The effect of the aryl ring on isolated enzyme activity	133
5.4	Investigation of the possible binding modes for the pyrazolo[1,5- <i>a</i>]pyridines with the p110 α active site.....	134
5.5	Thiazole series	137
5.6	Summary	138
5.7	Future Work.....	139
Chapter 6.	Experimental.....	141
6.1	Chemistry.....	141
6.2	Enzyme assays	141
6.3	Cellular assay	142
6.4	Synthesis of Pyrido[1,2- <i>a</i>]pyrimidines	143
6.5	Synthesis of Pyrazolo[1,5- <i>a</i>]pyridines.....	190
References	220
Appendix A.	232
p110 isozymes sequence kinase domain.	232

ERRAT Plots for kinase domain of template structures (p110 α , p110 γ) and p110 β comparative models	235
---------------------------------------------------------------------------------------------------------------------------------	-----

Declaration and Preface

This is to certify that:

1. the thesis comprises only my original work towards the PhD except where indicated below;
2. due acknowledgment has been made in the text to all other material used.

My project was part of an established and multi-disciplinary drug development program exploring inhibitors of PI3K, comprised of Chemistry, Biology (Prof. Bill Denny and Prof. Bruce Baguely, ACSRC) and Molecular Biology (Prof. Peter Sheperd, MMP). To indicate the rationale for exploring the sulfonyl-thiazole linker moiety in Chapters 4 and the observed SAR presented in Chapter 5, these Chapters include data from compounds not synthesised by the Author: Chapter 4 (Tables 4.1 and 4.2) and Chapter 5 (Table 5.1) present data from a series of compounds synthesised by Jackie Kendall (ACSRC). Furthermore, molecular modelling work conducted by Raphael Frederick (ACSRC) was included to illustrate a hypothetical binding mode for the series, presented in Chapter 4 (Figures 4.2 and 4.3).

Compounds synthesised in the PI3K program were screening against isolated enzyme panel consisting of p110 α , p110 β and p110 δ . The IC₅₀ values are obtained from a kinase assay that measures radioactive phosphatidylinositol 3-phosphate (PIP), produced by the p110-p85 heterodimer phosphorylation of phosphatidylinositol (PI). Claire Mawson, Jo Yu (ACSRC), Kitty Cho, Sharada Kolekar, Woo-Jeong Lee and Alisha Malik (MMP) ran these assays under the supervision of Prof Peter Sheperd.

Cellular antiproliferative data were also obtained from two human tumour cell lines, by measuring radioactive thymidine incorporation. NZB5 is derived from a brain cancer, and has wild-type PI3K, while NZOV9 (an ovarian tumour cell line) contains mutation Y1021C in the p110 α helical domain. Emma Richardson, Wayne Joseph, Laura Broome, and Elaine Marshall carried out the cellular assays, under the supervision of Prof. Bruce Baguely.

Abbreviations Chemistry

Ac:	Acetyl
AcOH:	Acetic acid
APCI:	Atmospheric pressure chemical ionization
aq.:	Aqueous
Ar:	Aromatic
Boc / BOC:	<i>tert</i> -Butyloxycarbonyl
br:	Broad
Bu:	Butyl
C:	Celsius
cat.:	Catalytic
cm:	Centimetre
Conc.:	Concentrated
COSY:	Correlation spectroscopy
d:	Doublet
dd:	Doublet of doublets
ddd:	Doublet of doublet of doublets
dil.:	Dilute
DIPEA:	Diisopropylethylamine
DMAP:	4-Dimethylaminopyridine
DMF:	<i>N,N</i> -Dimethylformamide
DMSO:	Dimethyl sulfoxide
dq:	Doublet of quartets
dt:	Doublet of triplets
EDG:	Electron donating group
EDTA:	Ethylenediaminetetraacetic acid
EI:	Electron impact ionization
Et:	Ethyl
EtOAc:	Ethyl acetate
EtOH:	Ethanol
eV:	Electron volt
g:	Gram
hr:	Hour
HPLC:	High performance liquid chromatography

HRMS:	High resolution mass spectroscopy
HSQC:	Heteronuclear single quantum coherence
Hz:	Hertz
ⁱ Pr / <i>i</i> -Pr:	<i>iso</i> -Propyl
LDA:	Lithium diisopropylamide
LHMDS:	Lithium hexamethyldisilazide
lit.:	Literature
m.p.:	Melting point
m:	Multiplet (NMR)
<i>m</i> -CPBA:	<i>meta</i> -Chloroperoxybenzoic acid
Me:	Methyl
MeOH:	Methanol
mg:	Milligram
MHz:	Megahertz
min:	Minute
mmol:	Millimol
Ms:	Methanesulfonyl, Mesyl
ⁿ Bu / <i>n</i> -Bu:	<i>n</i> -Butyl
NMR:	Nuclear magnetic resonance
NO:	Nitric oxide
NOE:	Nuclear Overhauser effect
Ph:	Phenyl
ppm:	Part per million
Pr:	Propyl
py:	Pyridine
q:	Quartet
qd:	Quartet of Doublets
r.t.:	Room temperature
s:	Singlet (NMR)
T / temp.:	Temperature
t:	Triplet
TBAB:	Tetrabutylammonium Bromide
^t Bu / <i>t</i> -Bu:	<i>tert</i> -Butyl
td:	Triplet of doublets
TFA:	Trifluoroacetic acid
THF:	Tetrahydrofuran

TLC:	Thin layer chromatography
TMS:	Trimethylsilyl, tetramethylsilane
Ts:	<i>para</i> -Toluenesulfonyl, Tosyl

Amino acids

Ala	(A)	Alanine
Arg	(R)	Arginine
Asn	(N)	Asparagine
Asp	(D)	Aspartic acid
Cys	(C)	Cysteine
Gln	(Q)	Glutamine
Glu	(E)	Glutamic acid
Gly	(G)	Glycine
His	(H)	Histidine
Ile	(I)	Isoleucine
Leu	(L)	Leucine
Lys	(K)	Lysine
Met	(M)	Methionine
Phe	(F)	Phenylalanine
Pro	(P)	Proline
Ser	(S)	Serine
Thr	(T)	Threonine
Try	(W)	Tryptophan
Tyr	(Y)	Tyrosine
Val	(V)	Valine

Abbreviations (Molecular and Cellular biology)

Akt/PKB:	v-akt murine thymoma viral oncogene homolog 1
ATM:	Ataxia telangiectasia mutated gene product
AML:	Acute myeloid leukemia
BAD:	Bcl2-antagonist of cell death
CDK:	Cyclin dependent kinase
CK2:	Casein kinase 2
cDNA:	Complimentary Deoxyribonucleic acid

DNA:	Deoxyribonucleic acid
DNA-PK:	DNA-dependent protein kinase
EGFR:	Epidermal growth factor receptor
GBM:	Glioblastoma multiforme
GPCR:	G-protein-coupled receptor
GSK3:	Glycogen synthesis kinase 3
HIF-1 α :	Hypoxia-inducible factor 1 α
IRS:	Insulin receptor substrate
mTOR:	Mammalian target of rapamycin
MLCK:	Myosin light chain kinase
n.d	Not determined
PAF:	Platelet activated factor
PH:	Pleckstrin homology
PI3K :	Phosphatidylinositol 3-kinase
PI:	Phosphatidylinositol
PIP:	Phosphatidylinositol 4-phosphate
PIP ₂ :	Phosphatidylinositol 4,5-bisphosphate
PIP ₃ :	Phosphatidylinositol 3,4,5-trisphosphate
PKB/Akt:	Protein kinase B
PKC:	Protein kinase C
PIKK:	PI3K-related kinase
PLK:	Polo-like kinase
PTEN:	Phosphatase and tensin homologue
PIK3CA:	cDNA for the human p110 α subunit of PI3K
PIK3CB:	cDNA for the human p110 β subunit of PI3K
PIK3CD:	cDNA for the human p110 δ subunit of PI3K
PIK3CG:	cDNA for the human p110 γ subunit of PI3K
PK:	Pharmacokinetics
RAS:	oncogenes causing Rat sarcoma
RTK:	Receptor tyrosine kinase
VEGF:	Vascular endothelial growth factor
Vps34:	Vacuolar protein sorting 34

